Evaluation of the effect of N-acetyl-glucosamine administration on biomarkers for cartilage metabolism

Evaluation of the effect of N-acetyl-glucosamine administration on biomarkers for cartilage metabolism - Evaluation of the effect of N-acetyl-glucosamine administration on biomarkers for cartilage metabolism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020589

Enrollment

120

Registered

2017-09-30

Start date

2016-01-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese adult without clinical and radiographic evidence of knee osteoarthritis

Interventions

N-acetyl-glucosamine (500 mg/day, weeks 16 during the intervention) Placebo (500 mg/day, weeks 16 during the intervention)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Japanese adult (aged 40-74) without clinical and radiographic evidence of knee osteoarthritis

Exclusion criteria

Exclusion criteria: 1.Subjects with gout or rheumatoid arthritis 2.Subjects with surgical treatment of joint performed or its necessity 3.Subjects with routine use of health foods which are good for bone or joint 4.Subjects with the presence of any clinically significant conditions judged by the medical investigator to preclude the subject's participation in the study

Design outcomes

Primary

Measure	Time frame
change in C2C/PIICP (weeks 16 during the intervention) chnge in C2C/PIICP (weeks 8 and 12 during the intervention, weeks 8 after intervention)	—

Secondary

Measure	Time frame
change in C2C (weeks 8, 12 and 16 during the intervention, weeks 8 after intervention) change in PIICP (weeks 8, 12 and 16 during the intervention, weeks 8 after intervention)	—

Countries

Japan

Contacts

Public ContactTakashi Nakagawa

TTC Co.,Ltd. Clinical Research Planning Department

t.nakagawa@ttc-tokyo.co.jp03-5459-5329

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026